The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

Analysts at StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s ...

1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court ...

Date and Time: Monday, March 10, 2025 at 1:40 p.m. Eastern time About Keros Therapeutics, Inc.

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...